Philip Wagenheim Biography and Net Worth

Director of Immunome

Mr. Wagenheim has more than 28 years of experience in the financial industry and is the Managing Partner of Broadband Capital Partners, LLC, a middle-market private equity sponsor focused on growth companies and industry consolidations. Prior to Broadband Capital Partners, he was the vice-chairman of Broadband Capital Management LLC, an investment and merchant bank he co-founded in 2000. Mr. Wagenheim has extensive experience with public and private growth equity investments, including Zynerba Pharmaceuticals (Nasdaq: ZYNE), ExamWorks (Nasdaq: EXAM), Vroom.com (Nasdaq: VRM) and Montrose Environmental Group. In connection with Zynerba’s recapitalization, Mr. Wagenheim was named President and a Director of the company, serving as a director until the company’s initial public offering in August 2015 led by Jefferies and Piper Jaffray. Mr. Wagenheim received his degree in Business Administration from the University of Miami.

What is Philip Wagenheim's net worth?: The estimated net worth of Philip Wagenheim is at least $7.66 million as of March 20th, 2026. Mr. Wagenheim owns 369,347 shares of Immunome stock worth more than $7,663,950 as of March 24th. This net worth evaluation does not reflect any other assets that Mr. Wagenheim may own. Learn More about Philip Wagenheim's net worth.
How do I contact Philip Wagenheim?: The corporate mailing address for Mr. Wagenheim and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at [email protected]. Learn More on Philip Wagenheim's contact information.
Has Philip Wagenheim been buying or selling shares of Immunome?: In the last ninety days, Philip Wagenheim has sold $1,335,626.00 of Immunome stock. Most recently, Philip Wagenheim sold 28,200 shares of the business's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $20.65, for a transaction totalling $582,330.00. Following the completion of the sale, the director now directly owns 341,147 shares of the company's stock, valued at $7,044,685.55. Learn More on Philip Wagenheim's trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Isaac Barchas (Director), Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), Bruce Turner (Insider), and Philip Wagenheim (Director). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 9 times. They purchased a total of 230,918 shares worth more than $2,682,903.29. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 448,200 shares worth more than $9,666,394.00. The most recent insider tranaction occured on March, 23rd when Director Philip Wagenheim sold 28,200 shares worth more than $582,330.00. Insiders at Immunome own 7.7% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 3/23/2026.

Philip Wagenheim Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/23/2026	Sell	28,200	$20.65	$582,330.00	341,147
3/20/2026	Sell	36,800	$20.47	$753,296.00	369,347

Philip Wagenheim Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $20.61

$19.91

$20.48

50 Day Range

MA: $22.76

$20.02

$26.97

2 Week Range

Now: $20.61

$5.15

$27.65

Volume

116,056 shs

Average Volume

1,544,920 shs

Market Capitalization

$2.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.12